The long noncoding RNA of RMRP is downregulated by PERK, which induces apoptosis in hepatocellular carcinoma cells. 2021

Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa 454, Toon, Ehime, 791-0295, Japan.

Endoplasmic reticulum (ER) stress plays an important role in hepatocyte degeneration, especially in patients with chronic liver injury. Protein kinase R-like endoplasmic reticulum kinase (PERK) is a key molecule in ER stress. PERK may contribute to apoptotic cell death in HCC, however the details of the mechanism are not clear. In this study, we identified PERK-associated molecules using transcriptome analysis. We modulated PERK expression using a plasmid, tunicamycin and siRNA against PERK, and then confirmed the target gene expression with real-time PCR and Northern blotting. We further analyzed the apoptotic function. Transcriptome analysis revealed that expression of the RNA component of mitochondrial RNA processing endoribonuclease (RMRP), which is a long noncoding RNA, was strongly correlated with the function of PERK. The expression of RMRP was correlated with the expression of PERK in experiments with the siRNA and PERK plasmid in both HCC cell lines and human HCC tissue. Furthermore, RMRP downregulation induced apoptotic cell death. RMRP is downregulated by PERK, which induces apoptosis in HCC. RMRP could be a new therapeutic target to regulate HCC in patients with chronic liver diseases associated with ER stress.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014415 Tunicamycin An N-acetylglycosamine containing antiviral antibiotic obtained from Streptomyces lysosuperificus. It is also active against some bacteria and fungi, because it inhibits the glucosylation of proteins. Tunicamycin is used as tool in the study of microbial biosynthetic mechanisms.
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
January 2020, OncoTargets and therapy,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
September 2015, Medical oncology (Northwood, London, England),
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
July 2021, Proceedings of the National Academy of Sciences of the United States of America,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
January 2018, Cancer cell international,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
May 2017, Oncotarget,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
January 2019, OncoTargets and therapy,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
December 2023, Molecular and cellular probes,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
January 2019, Technology in cancer research & treatment,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
February 2021, International journal of molecular sciences,
Atsushi Yukimoto, and Takao Watanabe, and Kotaro Sunago, and Yoshiko Nakamura, and Takaaki Tanaka, and Yohei Koizumi, and Osamu Yoshida, and Yoshio Tokumoto, and Masashi Hirooka, and Masanori Abe, and Yoichi Hiasa
September 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Copied contents to your clipboard!